TurnerTrends Stock Rating Report for AMGN
Data valid for week beginning July 14, 2008
|
AMGN [News]
|
Amgen Inc
|
Company Profile
"Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation, and oncology. The company's principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia- Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections- and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. Amgen has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa- a co-promotion agreement with Wyeth for marketing and selling of ENBREL- and a collaboration agreement with Cytokinetics, Inc. primarily with respect to out-licensing denosumab in Japan to Daiichi Sankyo. The company markets its products to healthcare providers including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada. Amgen, Inc. was founded in 1980 and is based in Thousand Oaks, California."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Fri, 18 Jul 2008 09:45:00 Etc/GMT | Going bi-coastal (at Fortune) | | Thu, 17 Jul 2008 20:43:01 Etc/GMT | AMGEN INC Files SEC form 8-K, Other Events (EDGAR Online) | | Thu, 17 Jul 2008 20:39:00 Etc/GMT | Amgen Announces Webcast of 2008 Second Quarter Financial Results (Business Wire) | | Thu, 17 Jul 2008 15:50:00 Etc/GMT | Trading Biotech With ETFs (at Minyanville.com) | | Wed, 16 Jul 2008 20:06:34 Etc/GMT | A Big Upgrade for Celgene (at Motley Fool) | | Wed, 16 Jul 2008 19:45:27 Etc/GMT | Big Biotech Booms But IBB Falls Flat (at Seeking Alpha) | | Wed, 16 Jul 2008 19:36:38 Etc/GMT | J&J's Lesson to Investors: Diversify! (at Motley Fool) | | Tue, 15 Jul 2008 22:46:00 Etc/GMT | Study Showed Half of Patients Treated with Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission and 80 Percent Had No Progression of Joint Damage in Active Early Rheumatoid Arthritis (Business Wire) | | Tue, 15 Jul 2008 20:02:00 Etc/GMT | Biotech Stocks: Genentech, J&J stoke drug sector (at MarketWatch) | | Tue, 15 Jul 2008 19:34:00 Etc/GMT | J&J profit climbs on low dollar, medical-device sales (at MarketWatch) | | Tue, 15 Jul 2008 18:10:48 Etc/GMT | Amgen Earnings Call scheduled for Mon, July 28 (CCBN) | | Tue, 15 Jul 2008 17:26:00 Etc/GMT | J&J posts higher net, citing dollar woes and medical-device sales (at MarketWatch) | | Tue, 15 Jul 2008 13:43:00 Etc/GMT | Stakes in Fannie, Freddie a Drag for Some Pro Investors (Indie Research) | | Mon, 14 Jul 2008 23:42:00 Etc/GMT | [$$] Amgen Says Bone Drug Cut Fractures in Big Trial (at The Wall Street Journal Online) | | Mon, 14 Jul 2008 23:01:10 Etc/GMT | Bristol's Orencia can ease juvenile arthritis-study (at Reuters) | | Mon, 14 Jul 2008 21:35:46 Etc/GMT | Yahoo's current board versus Icahn's challengers (AP) | | Mon, 14 Jul 2008 19:15:00 Etc/GMT | Biotech Stocks: Drug stocks U-turn into negative territory (at MarketWatch) | | Mon, 14 Jul 2008 18:36:00 Etc/GMT | Amgen, J&J Come To Truce in Oncology Marketing Suit (at The Wall Street Journal Online) | | Mon, 14 Jul 2008 18:25:20 Etc/GMT | UPDATE - Drug prevents bone loss in prostate cancer - Amgen (at Reuters) | | Mon, 14 Jul 2008 18:21:25 Etc/GMT | Foolish Forecast: J&J Trudges Along (at Motley Fool) | News provided by Yahoo! Finance |
|
